Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Imiquimod in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities

Trial Profile

Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Imiquimod in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2018

At a glance

  • Drugs Imiquimod (Primary) ; Fluorouracil
  • Indications Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Aug 2018 Planned End Date changed from 28 Sep 2019 to 14 Oct 2019.
    • 03 Aug 2018 Planned primary completion date changed from 27 Jul 2019 to 19 Aug 2019.
    • 03 Aug 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top